Nippon Shinyaku Co. Ltd.
www.nippon-shinyaku.co.jp
Latest From Nippon Shinyaku Co. Ltd.
Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements
The latest drug development news and highlights from our US FDA Performance Tracker.
Legal Challenge To First Japan Rituxan Biosimilar Dismissed
First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.
Missed BEAT Removes Tough Sell For United Therapeutics
The Phase III failure of esuberaprost combined with Tyvaso in pulmonary arterial hypertension has prompted United Therapeutics to stop developing a therapy that was already facing an uphill battle for potentially meager returns.
Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T
Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cancer
- Cardiovascular
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Nippon Shinyaku Co. Ltd.
- Senior Management
-
Shigenobu Maekawa, Pres.
Taro Sakurai, Gen. Mgr., Fin. & Accounting
Akira Matsuura, Gen. Mgr., R&D - Contact Info
-
Nippon Shinyaku Co. Ltd.
Phone: (81) 75 321 1111
14 Nishinosho Monguchi-cho, Kisshoin
Minami-ku
Kyoto, 601-8550
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice